Entries by Citron Research

,

NVIDIA to Trade Back to $130

NVIDIA: The Moment that Separates the Gamblers from the Investors NVDA to Trade back to $130       Take your profits and move on to Google (Alphabet) (NASDAQ:GOOGL).  Exposure to the identical array of “sexy businesses” with less risk on the downside. In the recent frenzy in NVIDIA shares, it has added more to […]

,

Citron Provides New Proof Why Mallinckrodt is on its way to ZERO

Express Scripts lets the genie out the bottle!!!! When Jim Chanos Speaks – Citron Listens. First Enron, Then Valeant, Now Mallinckrodt.   Mallinckrodt is the most reviled company in the pharmaceutical industry.  Its unsavory business practices have only survived in the “post Valeant” era because of the direct business support of Express Scripts, their “co-conspirator”. […]

,

Could Blackberry be the Next NVIDIA?

Citron learns from history that we could be in the first stages of a “WOW” move from Blackberry BlackBerry 24 month target:  $20. or  Likely Buyout Target at a Sizeable Premium Blackberry as the next NVIDIA An interesting point not known by most NVDA shareholders, and definitely not talked about on CNBC — While the enterprise […]

,

IF YOU DON’T BELIEVE CITRON BELIEVE THE SCIENCE

To Reveal the True Value of Exact Sciences (NASDAQ:EXAS) Listen to the Highly Respected Company that is the ”Science” behind Exact Sciences Short Term Target Reaffirmed at $20 … Long Term Looks Dire   Citron is surprised that neither investors nor analysts properly analyzed the important disclosure from Exact on April 27th.   Citron notes that […]

, , ,

Citron Research exposes Exact Sciences and PROVES beyond ANY doubt why this stock will soon be cut in half

Every Man and Woman Over The Age of 50 MUST read this report from Citron Research Short term target:  $20. 3 to 5 Years:  Likely Single Digit, Potential 0. Exact Sciences (NASDAQ:EXAS) pushes a cancer test (Cologuard) to the public, inferior by its own admission, and loses money doing it.  That is why this $4 billion company […]